Search results for "Mesh"

showing 10 items of 885 documents

Integrating genome-wide genetic variations and monocyte expression data reveals trans-regulated gene modules in humans.

2011

One major expectation from the transcriptome in humans is to characterize the biological basis of associations identified by genome-wide association studies. So far, few cis expression quantitative trait loci (eQTLs) have been reliably related to disease susceptibility. Trans-regulating mechanisms may play a more prominent role in disease susceptibility. We analyzed 12,808 genes detected in at least 5% of circulating monocyte samples from a population-based sample of 1,490 European unrelated subjects. We applied a method of extraction of expression patterns—independent component analysis—to identify sets of co-regulated genes. These patterns were then related to 675,350 SNPs to identify maj…

MaleCancer ResearchGene ExpressionGenome-wide association studyGenetic NetworksCoronary Artery Disease[SDV.GEN] Life Sciences [q-bio]/GeneticsCardiovascularMESH: MonocytesMonocytesMESH: HypertensionTranscriptomes0302 clinical medicineMESH: ProteinsMESH: Genetic VariationGenetics (clinical)GeneticsMESH: Aged0303 health scienceseducation.field_of_studyMESH: Middle AgedMESH: Polymorphism Single NucleotideIntracellular Signaling Peptides and ProteinsMESH: Genetic Predisposition to DiseaseGenomicsMESH: Transcription FactorsMiddle AgedMESH: Ribosomal ProteinsMESH: Gene Expression Regulation3. Good healthHypertensionMedicineFemaleMESH: Diabetes Mellitus Type 1Research ArticleAdultRibosomal Proteinslcsh:QH426-470PopulationQuantitative Trait LociLocus (genetics)Single-nucleotide polymorphismBiologyQuantitative trait locusPolymorphism Single Nucleotide03 medical and health sciencesMESH: Gene Expression ProfilingGenome Analysis ToolsGeneticsGenome-Wide Association StudiesHumansGenetic Predisposition to DiseaseGene NetworkseducationMolecular BiologyBiologyEcology Evolution Behavior and SystematicsMESH: Genome Human030304 developmental biologyGenetic associationAdaptor Proteins Signal TransducingAged[SDV.GEN]Life Sciences [q-bio]/GeneticsMESH: HumansGenome HumanGene Expression ProfilingGenetic VariationProteinsHuman GeneticsMESH: AdultAtherosclerosisMESH: MaleMESH: Quantitative Trait LociGene expression profilingCeliac Diseaselcsh:GeneticsDiabetes Mellitus Type 1Gene Expression RegulationExpression quantitative trait lociGenetics of DiseaseMESH: Genome-Wide Association StudyMESH: MuramidaseMuramidaseGenome Expression AnalysisMESH: Female030217 neurology & neurosurgeryMESH: Celiac DiseaseGenome-Wide Association StudyTranscription Factors
researchProduct

Maternal medication use and the risk of brain tumors in the offspring: The SEARCH international case-control study

2006

International audience; N-nitroso compounds (NOC) have been associated with carcinogenesis in a wide range of species, including humans. There is strong experimental data showing that nitrosamides (R(1)NNO.COR(2)), a type of NOC, are potent neuro-carcinogens when administered transplacentally. Some medications are a concentrated source of amides or amines, which in the presence of nitrites under normal acidic conditions of the stomach can form NOC. Therefore, these compounds, when ingested by women during pregnancy, may be important risk factors for tumors of the central nervous system in the offspring. The aim of the present study was to test the association between maternal use of medicat…

MaleCancer ResearchMESH: Maternal-Fetal ExchangeMESH: Pregnancy0302 clinical medicinePregnancyRisk FactorsMESH: Risk FactorsMESH: ChildRecall biasEpidemiologyMedicine030212 general & internal medicineAminesChildMaternal-Fetal Exchangeeducation.field_of_studyBrain NeoplasmsN-nitroso compoundsMESH: AminesMESH: InfantMESH: AmidesMESH: Case-Control StudiesMESH: Mothers3. Good healthOncologyChild Preschool030220 oncology & carcinogenesisMESH: Brain NeoplasmsFemaleDisease SusceptibilityAdultmedicine.medical_specialtyAdolescentOffspringcase-control studyPopulationMESH: Disease SusceptibilityMothers[SDV.CAN]Life Sciences [q-bio]/Cancerchildhood brain tumors03 medical and health sciencesInternal medicineGliomamaternal medicationHumansRisk factoreducationMESH: AdolescentPregnancyMESH: Humansbusiness.industryMESH: Child PreschoolCase-control studyInfantMESH: Adultmedicine.diseaseAmidesMESH: MaleCase-Control StudiesbusinessMESH: FemaleInternational Journal of Cancer
researchProduct

Occupational factors and risk of adult bone sarcomas:a multicentric case-control study in Europe

2006

International audience; We investigated the association between occupational factors and risk of bone sarcoma, a rare tumor with a largely unknown aetiology. A multicentric case-control study was conducted in 7 European countries in 1995-97. Ninety-six cases aged 35-69 years with a centrally reviewed diagnosis of bone sarcoma (68 chondrosarcomas and 28 osteosarcomas) were compared to 2,632 population (68%) or colon cancer (32%) controls. Subjects were interviewed to obtain information on occupational, medical and reproductive history, smoking and alcohol consumption and selected exposures including use of pesticides. Response proportions were 90% among cases and 66% among controls. Odds rat…

MaleCancer ResearchMESH: OsteosarcomaMESH: ReproductionMESH: Occupational Exposure0302 clinical medicineMESH: Risk FactorsRisk FactorsEpidemiologyadult bone sarcomasOdds Ratio030212 general & internal medicineeducation.field_of_studyOsteosarcomaMESH: Middle AgedReproductionResearch Support Non-U.S. Gov'tSmokingMESH: ChondrosarcomaMiddle AgedMESH: Bone NeoplasmsMESH: Interviews as TopicMESH: Case-Control Studies3. Good healthEuropeMulticenter StudyOncology030220 oncology & carcinogenesisColonic NeoplasmsFemaleSarcomamulticentric case-control studyAdultmedicine.medical_specialtyMESH: SmokingAlcohol DrinkingPopulationChondrosarcomaBone NeoplasmsBone SarcomaOccupational medicineInterviews as Topic03 medical and health sciencesInternal medicineOccupational ExposuremedicineJournal ArticlewoodworkersHumansComparative StudyRisk factoreducationMESH: Colonic NeoplasmsMESH: Humansbusiness.industryCase-control studyoccupational risk factorsMESH: AdultOdds ratiopesticidesmedicine.diseaseMESH: MaleMESH: Odds RatioSurgery[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieCase-Control Studies[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieMESH: EuropebusinessMESH: FemaleMESH: Alcohol Drinking
researchProduct

Influence of sample return time and ambient temperature on the performance of an immunochemical faecal occult blood test with a new buffer for colore…

2016

IF 2.415; International audience; The haemoglobin concentration measured by faecal immunochemical tests (FIT) may be decreased in cases of delayed sample return or high temperature. It is an issue of great importance. The aim of this study was to investigate the effects of sample return time and of season on the performance of an FIT (FOB-Gold) with a new buffer. The study included 20 371 participants involved in the French organized colorectal cancer (CRC) screening programme. The probability of a positive screening test, detection rates and positive predictive values for CRC and advanced adenoma were analysed according to sample return time and season of screening. A sample of positive FI…

MaleCancer ResearchMultivariate analysisTime FactorsEpidemiologyColorectal cancerMESH: Reagent Kits DiagnosticMESH : AgedMESH : HemoglobinsMESH : Early Detection of Cancer[ SDV.CAN ] Life Sciences [q-bio]/CancerReturn timeScreening programmeImmunoenzyme TechniquesHemoglobinsMESH : Specimen HandlingMESH : FemaleMESH : Neoplasm StagingMESH : Reagent Kits DiagnosticMESH : TemperatureEarly Detection of CancerMESH: AgedMESH: Middle AgedMESH : PrognosisTemperatureMESH: Follow-Up StudiesMESH: Neoplasm StagingMiddle AgedPrognosisPredictive valueMESH: TemperatureMESH: HemoglobinsMESH : Occult BloodOncologyColorectal cancer screeningOccult BloodFemaleSeasonsMESH : Colorectal NeoplasmsColorectal NeoplasmsMESH : Time FactorsAdenomamedicine.medical_specialtySample (material)MESH : Male[SDV.CAN]Life Sciences [q-bio]/CancerMESH: PrognosisSpecimen HandlingAnimal scienceMESH : Immunoenzyme TechniquesmedicineHumansMESH: Early Detection of CancerMESH : Middle AgedMESH: Specimen HandlingMESH: Immunoenzyme TechniquesAgedNeoplasm StagingMESH: AdenomaMESH: HumansMESH : Seasonsbusiness.industryMESH: Time FactorsMESH : HumansPublic Health Environmental and Occupational HealthMESH : Follow-Up Studiesmedicine.diseaseMESH: MaleSurgeryMESH : AdenomaReagent Kits DiagnosticFaecal occult blood testbusinessMESH: Occult BloodMESH: FemaleMESH: SeasonsMESH: Colorectal NeoplasmsFollow-Up Studies
researchProduct

Survival of European children and young adults with cancer diagnosed 1995-2002

2009

This study analyses survival in 40,392 children (age 0-14 years) and 30,187 adolescents/young adults (age 15-24 years) diagnosed with cancer between 1995 and 2002. The cases were from 83 European population-based cancer registries in 23 countries participating in EUROCARE-4. Five-year survival in countries and in regional groupings of countries was compared for all cancers combined and for major cancers. Survival for 15 rare cancers in children was also analysed. Five-year survival for all cancers combined was 81% in children and 87% in adolescents/young adults. Between-country survival differences narrowed for both children and adolescents/young adults. Relative risk of death reduced signi…

MaleCancer ResearchPediatricsMESH : Child PreschoolAdolescentsMESH: Epidemiologic Methods[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineMESH : ChildNeoplasmsMESH: ChildEpidemiologyMESH: NeoplasmsMESH : Female030212 general & internal medicineYoung adultChildChildrenChildren & young adults; Cancer survivalMESH : InfantPopulation-based cancer registriesChildren & young adultsMESH: Infant3. Good healthEuropeEastern europeanOncologyMESH: Young AdultChild Preschool030220 oncology & carcinogenesisMESH : Rare DiseasesRare tumoursFemaleMESH: Rare Diseasesmedicine.medical_specialtyAdolescentMESH : MaleMESH : EuropeMESH : Young AdultSocio-culturale[SDV.CAN]Life Sciences [q-bio]/CancerMESH : Epidemiologic MethodsYoung Adult03 medical and health sciencesRare DiseasesSDG 3 - Good Health and Well-beingMESH : AdolescentmedicineHumansPreschoolAdolescents; Cancer survival; Children; Europe; Population-based cancer registries; Rare tumours; Young adults; Adolescent; Child; Child Preschool; Epidemiologic Methods; Europe; Female; Humans; Infant; Male; Neoplasms; Rare Diseases; Young Adult; Oncology; Cancer ResearchSurvival analysisMESH: AdolescentMESH: Humansbusiness.industryMESH: Child PreschoolMESH : HumansInfantCancermedicine.diseaseMESH : NeoplasmsCancer survivalMESH: MaleCancer registryEl NiñoRelative riskMESH: EuropeEpidemiologic MethodsbusinessMESH: FemaleYoung adults
researchProduct

The DYRK1A gene is a cause of syndromic intellectual disability with severe microcephaly and epilepsy.

2012

Background DYRK1A plays different functions during development, with an important role in controlling brain growth through neuronal proliferation and neurogenesis. It is expressed in a gene dosage dependent manner since dyrk1a haploinsufficiency induces a reduced brain size in mice, and DYRK1A overexpression is the candidate gene for intellectual disability (ID) and microcephaly in Down syndrome. We have identified a 69 kb deletion including the 5′ region of the DYRK1A gene in a patient with growth retardation, primary microcephaly, facial dysmorphism, seizures, ataxic gait, absent speech and ID. Because four patients previously reported with intragenic DYRK1A rearrangements or 21q22 microd…

MaleCandidate geneDown syndromeMicrocephalyAdolescentGenotypeBiologyProtein Serine-Threonine KinasesBioinformaticsFrameshift mutationEpilepsyAngelman syndromeIntellectual DisabilityGene OrderGeneticsmedicineHumansChildGenetics (clinical)GeneticsEpilepsyBase SequenceFaciesElectroencephalographySyndromeProtein-Tyrosine Kinasesmedicine.diseasePhenotypeChild PreschoolSpeech delayMutationMicrocephalyFemalemedicine.symptomHaploinsufficiencyJournal of medical genetics
researchProduct

Mutations in LCA5, encoding the ciliary protein lebercilin, cause Leber congenital amaurosis

2007

Contains fulltext : 53618.pdf (Publisher’s version ) (Closed access) Leber congenital amaurosis (LCA) causes blindness or severe visual impairment at or within a few months of birth. Here we show, using homozygosity mapping, that the LCA5 gene on chromosome 6q14, which encodes the previously unknown ciliary protein lebercilin, is associated with this disease. We detected homozygous nonsense and frameshift mutations in LCA5 in five families affected with LCA. In a sixth family, the LCA5 transcript was completely absent. LCA5 is expressed widely throughout development, although the phenotype in affected individuals is limited to the eye. Lebercilin localizes to the connecting cilia of photore…

MaleCandidate geneGenetics and epigenetic pathways of disease [NCMLS 6]genetic structuresMolecular Sequence DataOptic Atrophy Hereditary LeberNeuroinformatics [DCN 3]Biologymedicine.disease_causeCiliopathiesJoubert syndromeCell LineFrameshift mutationGenomic disorders and inherited multi-system disorders [IGMD 3]MiceTranslational research [ONCOL 3]Chlorocebus aethiopsPerception and Action [DCN 1]GeneticsmedicineNeurosensory disorders [UMCN 3.3]AnimalsHumansCiliaRats WistarEye ProteinsFrameshift MutationRenal disorder [IGMD 9]GeneticsMutationCiliumDisease gene identificationmedicine.diseasePhenotypeeye diseasesPedigreeRatsMice Inbred C57BLGenetic defects of metabolism [UMCN 5.1]Codon NonsenseCOS CellsFemalesense organsFunctional Neurogenomics [DCN 2]Microtubule-Associated ProteinsNature Genetics
researchProduct

The genomic and clinical landscape of fetal akinesia

2020

International audience; Fetal akinesia has multiple clinical subtypes with over 160 gene associations, but the genetic etiology is not yet completely understood.Methods: In this study, 51 patients from 47 unrelated families were analyzed using next-generation sequencing (NGS) techniques aiming to decipher the genomic landscape of fetal akinesia (FA).Results: We have identified likely pathogenic gene variants in 37 cases and report 41 novel variants. Additionally, we report putative pathogenic variants in eight cases including nine novel variants. Our work identified 14 novel disease-gene associations for fetal akinesia: ADSSL1, ASAH1, ASPM, ATP2B3, EARS2, FBLN1, PRG4, PRICKLE1, ROR2, SETBP1…

MaleCandidate geneMyopathyVARIANTSFetal akinesiaMESH: Ryanodine Receptor Calcium Release Channel0302 clinical medicineMESH: ChildGuanine Nucleotide Exchange FactorsMESH: Guanine Nucleotide Exchange FactorsExomeCopy-number variationChildExomeMESH: High-Throughput Nucleotide SequencingGenetics (clinical)GeneticsArthrogryposisArthrogryposis0303 health sciencesMESH: Infant NewbornMESH: Genetic Predisposition to DiseaseHigh-Throughput Nucleotide SequencingRNA-Binding ProteinsMESH: Infant3. Good healthFetal DiseasesCopy-number variationMESH: Fetal DiseasesMESH: Young AdultChild PreschoolASAH1FemaleMESH: DNA Copy Number Variationsmedicine.symptomAdultGENETICSAdolescentDNA Copy Number VariationsMESH: Trans-ActivatorsMESH: ArthrogryposisBiologyASPMYoung Adult03 medical and health sciencesMuscular DiseasesmedicineHumansGenetic Predisposition to DiseaseGene030304 developmental biologyMESH: Adolescent[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/PediatricsMESH: HumansMUTATIONSMESH: Child PreschoolInfant NewbornMESH: Muscular DiseasesInfantNEMALINE MYOPATHYRyanodine Receptor Calcium Release ChannelMESH: Adultmedicine.diseaseCongenital myopathyMESH: MaleMESH: RNA-Binding Proteins[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticsDISTAL ARTHROGRYPOSISTrans-ActivatorsMESH: Female030217 neurology & neurosurgery
researchProduct

A very mild phenotype of Charcot-Marie-Tooth disease type 4H caused by two novel mutations in FGD4

2019

Abstract Background Mutations in the FGD4 gene cause an autosomal recessive demyelinating peripheral neuropathy referred to as CMT4H, characterized by its onset in infancy or early-childhood and its slow progression. Methods The clinical and genetic status of two patients with CMT4H was studied, performing genetic testing with a panel of genes and analysing FGD4 mRNA expression by quantitative PCR. Results Two novel FGD4 variants (c.514delG and c.2211dupA) were identified in two mildly affected Spanish siblings with CMT4H, and with disease onset in late adolescence/adulthood (one of them remaining asymptomatic at 20). On examination, foot deformity was observed without weakness or sensory i…

MaleCharcot-Marie-ToothPathologymedicine.medical_specialtyAdolescentFGD4medicine.disease_causeAsymptomaticYoung Adult03 medical and health sciences0302 clinical medicineCharcot-Marie-Tooth DiseaseCharcot-Marie-Tooth disease type 4HCMT4HmedicineHumans030212 general & internal medicineAlleleFrameshift MutationGeneAllelesGenetic testingMutationmedicine.diagnostic_testbusiness.industrySiblingsCMTMicrofilament Proteinsmedicine.diseasePhenotypePedigreeNeuropathyPhenotypePeripheral neuropathyNeurologyFemaleNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgeryJournal of the Neurological Sciences
researchProduct

Factors that predict response of patients with hepatitis C virus infection to boceprevir

2012

Background & Aims Little is known about factors associated with a sustained virologic response (SVR) among patients with hepatitis C virus (HCV) infection to treatment with protease inhibitors. Methods Previously untreated patients (from the Serine Protease Inhibitor Therapy 2 [SPRINT-2] trial) and those who did not respond to prior therapy (from the Retreatment with HCV Serine Protease Inhibitor Boceprevir and PegIntron/Rebetol 2 [RESPOND-2] trial) received either a combination of peginterferon and ribavirin for 48 weeks or boceprevir, peginterferon, and ribavirin (triple therapy) after 4 weeks of peginterferon and ribavirin (total treatment duration, 28–48 wk). A good response to interfer…

MaleCirrhosisMESH: Logistic ModelsHepacivirusMESH: Risk AssessmentGastroenterologyPolyethylene GlycolsMESH: Recombinant ProteinsMESH: Genotype0302 clinical medicineOdds RatioProspective StudiesMESH: Treatment OutcomeResponse to Therapy0303 health sciencesMESH: Polymorphism Single NucleotideGastroenterologyvirus diseases3. Good healthMESH: RNA ViralHCVDrug Therapy Combination030211 gastroenterology & hepatologyClinical Trial; Genetic; Prognostic Factors; Response to Therapy; Adult; Antiviral Agents; Biomarkers; Canada; Drug Therapy Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interleukins; Logistic Models; Male; Multivariate Analysis; Odds Ratio; Phenotype; Polyethylene Glycols; Polymorphism Single Nucleotide; Proline; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States; Viral Load; GastroenterologyViral loadmedicine.medical_specialtyMESH: InterleukinsGenotypeProlineInterferon alpha-2MESH: PhenotypeAntiviral AgentsRisk Assessment03 medical and health sciencesDrug TherapyGeneticMESH: RibavirinMESH: CanadaBoceprevirHumansPolymorphismMESH: ProlineMESH: HumansPrognostic FactorsInterleukinsMESH: AdultOdds ratiomedicine.diseaseUnited Statesdigestive system diseasesClinical trialLogistic ModelschemistryImmunologyMESH: FemaleBiomarkersTime Factorsmedicine.disease_causechemistry.chemical_compoundRisk FactorsInterferonMESH: Risk FactorsMESH: HepacivirusViralSingle NucleotideViral LoadHepatitis CClinical TrialRecombinant ProteinsEuropePhenotypeTreatment OutcomeCombinationRNA ViralFemaleMESH: Interferon-alphaMESH: Viral Loadmedicine.drugAdultMESH: Antiviral AgentsCanadaHepatitis C virusPolymorphism Single NucleotideMESH: Multivariate AnalysisInternal medicineRibavirinmedicineMESH: United States030304 developmental biologyMESH: Hepatitis CHepatologybusiness.industryRibavirinMESH: Time FactorsMESH: Biological MarkersInterferon-alpha[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Prospective StudiesMESH: MaleMESH: Odds RatioMESH: Drug Therapy CombinationMESH: Polyethylene GlycolsMultivariate AnalysisRNAInterferonsMESH: Europebusiness
researchProduct